Entero Therapeutics Discounted Cash Flow

The latest DCF fair value for ENTO is $0.0067. Investors often review this figure alongside Entero Therapeutics's historical trend and sector peers before judging valuation or financial health.

A DCF fair value of $0.0067 for Entero Therapeutics suggests the stock may be overvalued by roughly 99.8% at today's price. That does not mean the market is 'wrong'; it means the model's cash-flow assumptions imply a different intrinsic value. Stress-test the estimate by comparing it with historical valuation ranges and peer multiples.

After noting ENTO's DCF fair value ($0.0067), review year-over-year change, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.